What is Bad Blood: Secrets and Lies in a Silicon Valley Startup about?

Bad Blood is Wall Street Journal reporter John Carreyrou's account of Theranos, the blood-testing startup founded by Elizabeth Holmes that claimed its proprietary technology could run hundreds of diagnostic tests from a single finger-prick of blood. From its founding in 2003 through its collapse in 2018, Theranos raised nearly $900 million, reached a peak valuation of $9 billion, and made Holmes the youngest female self-made billionaire in America — all built on technology that didn't work and results that put patients at risk.

Carreyrou reconstructs the fraud through interviews with dozens of former employees, many of whom faced legal threats and nondisclosure agreements that kept them silent for years. The picture that emerges is of a culture built on fear, secrecy, and a founder's absolute unwillingness to hear that the science wasn't there. Holmes modeled herself on Steve Jobs — the black turtleneck, the reality-distortion field, the refusal to accept engineering limits as real limits. Her partner Ramesh "Sunny" Balwani enforced that culture through intimidation. Employees who raised concerns were fired or threatened; those who stayed learned to look away. The board, stacked with political luminaries rather than scientists or medical professionals, provided almost no meaningful oversight.

What makes Carreyrou's reporting land is the human cost. Theranos ran its unvalidated tests on real patients in Walgreens stores in Arizona and California. People received false positives for cancer, false negatives for HIV, abnormal results that sent them to doctors with imaginary problems. The company's internal Edison machines were so unreliable that Theranos secretly ran most samples on commercial Siemens analyzers — while telling patients the results came from proprietary technology. The fraud wasn't a victimless financial crime; it was a medical one.

The book is also a case study in how Silicon Valley's "fake it till you make it" ethos, its deference to charismatic founders, and its structural distrust of skeptics made the fraud possible for as long as it was. Sophisticated investors skipped due diligence because Holmes was compelling and the story was good. Journalists wrote hagiographies. The legal apparatus Holmes deployed against whistleblowers worked. Carreyrou's own investigation required years of source-building and legal battles before the story ran. Bad Blood is a warning about what happens when the mechanisms designed to catch fraud — boards, auditors, regulators, the press — are all neutralized at once.